Merck & Co Inc

Merck insider buying signals confidence in its oncology momentum, with executives buying shares as earnings rise—an indicator for investors to watch.

Merck insiders’ April 29 buy signals management confidence in oncology and vaccine growth, boosting investor sentiment amid upbeat social‑media buzz.

Merck insider trades reveal confidence in its digital‑first strategy, with EVP David Michael buying shares amid rising buzz and positive sentiment—potential upside for investors.

Merck insider buying shows confidence in its vaccine and oncology pipeline, suggesting solid mid‑term earnings growth amid mixed market sentiment.